Cargando…
A New Anti-Estrogen Discovery Platform Identifies FDA-Approved Imidazole Anti-Fungal Drugs as Bioactive Compounds against ERα Expressing Breast Cancer Cells
17β-estradiol (E2) exerts its physiological effects through the estrogen receptor α (i.e., ERα). The E2:ERα signaling allows the regulation of cell proliferation. Indeed, E2 sustains the progression of ERα positive (ERα+) breast cancers (BCs). The presence of ERα at the BC diagnosis drives their the...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8000495/ https://www.ncbi.nlm.nih.gov/pubmed/33805656 http://dx.doi.org/10.3390/ijms22062915 |
_version_ | 1783671012881072128 |
---|---|
author | Cipolletti, Manuela Bartoloni, Stefania Busonero, Claudia Parente, Martina Leone, Stefano Acconcia, Filippo |
author_facet | Cipolletti, Manuela Bartoloni, Stefania Busonero, Claudia Parente, Martina Leone, Stefano Acconcia, Filippo |
author_sort | Cipolletti, Manuela |
collection | PubMed |
description | 17β-estradiol (E2) exerts its physiological effects through the estrogen receptor α (i.e., ERα). The E2:ERα signaling allows the regulation of cell proliferation. Indeed, E2 sustains the progression of ERα positive (ERα+) breast cancers (BCs). The presence of ERα at the BC diagnosis drives their therapeutic treatment with the endocrine therapy (ET), which restrains BC progression. Nonetheless, many patients develop metastatic BCs (MBC) for which a treatment is not available. Consequently, the actual challenge is to complement the drugs available to fight ERα+ primary and MBC. Here we exploited a novel anti-estrogen discovery platform to identify new Food and Drug Administration (FDA)-approved drugs inhibiting E2:ERα signaling to cell proliferation in cellular models of primary and MBC cells. We report that the anti-fungal drugs clotrimazole (Clo) and fenticonazole (Fenti) induce ERα degradation and prevent ERα transcriptional signaling and proliferation in cells modeling primary and metastatic BC. The anti-proliferative effects of Clo and Fenti occur also in 3D cancer models (i.e., tumor spheroids) and in a synergic manner with the CDK4/CDK6 inhibitors palbociclib and abemaciclib. Therefore, Clo and Fenti behave as “anti-estrogens”-like drugs. Remarkably, the present “anti-estrogen” discovery platform represents a valuable method to rapidly identify bioactive compounds with anti-estrogenic activity. |
format | Online Article Text |
id | pubmed-8000495 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-80004952021-03-28 A New Anti-Estrogen Discovery Platform Identifies FDA-Approved Imidazole Anti-Fungal Drugs as Bioactive Compounds against ERα Expressing Breast Cancer Cells Cipolletti, Manuela Bartoloni, Stefania Busonero, Claudia Parente, Martina Leone, Stefano Acconcia, Filippo Int J Mol Sci Article 17β-estradiol (E2) exerts its physiological effects through the estrogen receptor α (i.e., ERα). The E2:ERα signaling allows the regulation of cell proliferation. Indeed, E2 sustains the progression of ERα positive (ERα+) breast cancers (BCs). The presence of ERα at the BC diagnosis drives their therapeutic treatment with the endocrine therapy (ET), which restrains BC progression. Nonetheless, many patients develop metastatic BCs (MBC) for which a treatment is not available. Consequently, the actual challenge is to complement the drugs available to fight ERα+ primary and MBC. Here we exploited a novel anti-estrogen discovery platform to identify new Food and Drug Administration (FDA)-approved drugs inhibiting E2:ERα signaling to cell proliferation in cellular models of primary and MBC cells. We report that the anti-fungal drugs clotrimazole (Clo) and fenticonazole (Fenti) induce ERα degradation and prevent ERα transcriptional signaling and proliferation in cells modeling primary and metastatic BC. The anti-proliferative effects of Clo and Fenti occur also in 3D cancer models (i.e., tumor spheroids) and in a synergic manner with the CDK4/CDK6 inhibitors palbociclib and abemaciclib. Therefore, Clo and Fenti behave as “anti-estrogens”-like drugs. Remarkably, the present “anti-estrogen” discovery platform represents a valuable method to rapidly identify bioactive compounds with anti-estrogenic activity. MDPI 2021-03-13 /pmc/articles/PMC8000495/ /pubmed/33805656 http://dx.doi.org/10.3390/ijms22062915 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Cipolletti, Manuela Bartoloni, Stefania Busonero, Claudia Parente, Martina Leone, Stefano Acconcia, Filippo A New Anti-Estrogen Discovery Platform Identifies FDA-Approved Imidazole Anti-Fungal Drugs as Bioactive Compounds against ERα Expressing Breast Cancer Cells |
title | A New Anti-Estrogen Discovery Platform Identifies FDA-Approved Imidazole Anti-Fungal Drugs as Bioactive Compounds against ERα Expressing Breast Cancer Cells |
title_full | A New Anti-Estrogen Discovery Platform Identifies FDA-Approved Imidazole Anti-Fungal Drugs as Bioactive Compounds against ERα Expressing Breast Cancer Cells |
title_fullStr | A New Anti-Estrogen Discovery Platform Identifies FDA-Approved Imidazole Anti-Fungal Drugs as Bioactive Compounds against ERα Expressing Breast Cancer Cells |
title_full_unstemmed | A New Anti-Estrogen Discovery Platform Identifies FDA-Approved Imidazole Anti-Fungal Drugs as Bioactive Compounds against ERα Expressing Breast Cancer Cells |
title_short | A New Anti-Estrogen Discovery Platform Identifies FDA-Approved Imidazole Anti-Fungal Drugs as Bioactive Compounds against ERα Expressing Breast Cancer Cells |
title_sort | new anti-estrogen discovery platform identifies fda-approved imidazole anti-fungal drugs as bioactive compounds against erα expressing breast cancer cells |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8000495/ https://www.ncbi.nlm.nih.gov/pubmed/33805656 http://dx.doi.org/10.3390/ijms22062915 |
work_keys_str_mv | AT cipollettimanuela anewantiestrogendiscoveryplatformidentifiesfdaapprovedimidazoleantifungaldrugsasbioactivecompoundsagainsteraexpressingbreastcancercells AT bartolonistefania anewantiestrogendiscoveryplatformidentifiesfdaapprovedimidazoleantifungaldrugsasbioactivecompoundsagainsteraexpressingbreastcancercells AT busoneroclaudia anewantiestrogendiscoveryplatformidentifiesfdaapprovedimidazoleantifungaldrugsasbioactivecompoundsagainsteraexpressingbreastcancercells AT parentemartina anewantiestrogendiscoveryplatformidentifiesfdaapprovedimidazoleantifungaldrugsasbioactivecompoundsagainsteraexpressingbreastcancercells AT leonestefano anewantiestrogendiscoveryplatformidentifiesfdaapprovedimidazoleantifungaldrugsasbioactivecompoundsagainsteraexpressingbreastcancercells AT acconciafilippo anewantiestrogendiscoveryplatformidentifiesfdaapprovedimidazoleantifungaldrugsasbioactivecompoundsagainsteraexpressingbreastcancercells AT cipollettimanuela newantiestrogendiscoveryplatformidentifiesfdaapprovedimidazoleantifungaldrugsasbioactivecompoundsagainsteraexpressingbreastcancercells AT bartolonistefania newantiestrogendiscoveryplatformidentifiesfdaapprovedimidazoleantifungaldrugsasbioactivecompoundsagainsteraexpressingbreastcancercells AT busoneroclaudia newantiestrogendiscoveryplatformidentifiesfdaapprovedimidazoleantifungaldrugsasbioactivecompoundsagainsteraexpressingbreastcancercells AT parentemartina newantiestrogendiscoveryplatformidentifiesfdaapprovedimidazoleantifungaldrugsasbioactivecompoundsagainsteraexpressingbreastcancercells AT leonestefano newantiestrogendiscoveryplatformidentifiesfdaapprovedimidazoleantifungaldrugsasbioactivecompoundsagainsteraexpressingbreastcancercells AT acconciafilippo newantiestrogendiscoveryplatformidentifiesfdaapprovedimidazoleantifungaldrugsasbioactivecompoundsagainsteraexpressingbreastcancercells |